Composition and method for preventing or treating fat pancreas and improving pancreatic lesion, diabetes or other related diseases caused by fat pancreas

Abstract

The invention relates to a composition and a method for preventing or treating fat pancreas and improving pancreatic lesions, diabetes mellitus or other related diseases caused by the fat pancreas. Specifically, the invention relates to application of a compound to preparation of a composition for reducing pancreatic fat content, preventing or treating fat pancreas or improving pancreatic lesions or other related diseases caused by the fat pancreas in an individual.

Description

[0001] This application is a divisional application of the Chinese patent application with application number 201680067605X, application date November 21, 2016, and invention name "Compositions and methods for preventing or treating fatty pancreas, improving pancreatic lesions, diabetes or other related diseases caused by fatty pancreas".

[0002] Related Applications

[0003] This application claims priority to U.S. Provisional Application No. 62 / 257,707, filed on November 19, 2015, the contents of which are incorporated herein by reference in their entirety. Technical Field

[0004] The present invention relates to a composition and method for preventing or treating fatty pancreas, improving pancreatic lesions caused by fatty pancreas, diabetes or other related diseases. Background Art

[0005] The pancreas is an organ in the human body that has both exocrine and endocrine functions. The exocrine part includes the acinus, which can secrete a variety of digestive enzymes, and the endocrine part includes the islets of Langerhans, which can secrete hormones such as insulin, which plays a very important role in maintaining blood sugar levels. Fat accumulation in the pancreas may affect pancreatic function, further causing pancreatic disease, diabetes or other related diseases. Specifically, diabetes is a disease of abnormal glucose metabolism. There are two different types of diabetes, including non-insulin-dependent or adult-onset, also known as type II diabetes; and insulin-dependent or juvenile-onset, also known as type I diabetes. In general, type II diabetes usually occurs in adults and is highly correlated with obesity. It can be controlled through proper exercise, diet and medication; type I diabetes patients are more common in children and adolescents. The patient's body cannot produce enough insulin and must be injected with insulin to maintain life.

[0006] Therefore, there is still a need to find an effective ingredient that can effectively reduce the pancreatic fat content of an individual and improve related symptoms. Summary of the invention

[0007] The present invention provides one or more compounds having the efficacy of reducing pancreatic fat content, preventing or treating fatty pancreas, improving pancreatic lesions caused by fatty pancreas, diabetes or other related diseases in an individual, wherein the compound is selected from the group consisting of: poncirin, isovitexin, eriodictyol, ergosterol, β-myrcene, hyperoside, (+)-catechin, palmitic acid ethyl ester, galangin, morin, sciadopitysin, didymin, gossypin, luteolin-7-glucoside, (+)-taxifolin, trans-cinnamic Acid, diosmin, linarin, homoorientin, xylitol, luteolin, swertiamarin, sodium lauryl sulfate, menthol, sucralose, mannitol, crospovidone, sorbitol, saccharin, glycerin, sodium benzoate, oxide red, pregelatinized starch, sodium cyclamate, sorbic acid, lemon oil, maltodextrin, citric acid, and butylated hydroxyanisole, and derivatives, metabolites and decomposition products thereof, and any combination thereof.

[0008] Therefore, in one aspect, the present invention proposes the use of the compound or its derivatives, metabolites or decomposition products for preparing a composition for reducing pancreatic fat content, preventing or treating fatty pancreas, improving pancreatic lesions caused by fatty pancreas, diabetes or other related diseases in an individual. The present invention also proposes a method for reducing pancreatic fat content, preventing or treating fatty pancreas, improving pancreatic lesions caused by fatty pancreas, diabetes or other related diseases in an individual in need by administering the compound or its derivatives, metabolites or decomposition products.

[0009] In some embodiments, the compound is selected from the group consisting of menthol, mannitol, eriodictyol, sucralose, and any combination thereof.

[0010] In some embodiments, the compound is (1) a combination of menthol, mannitol and eriodictyol, (2) a combination of mannitol and eriodictyol, (3) a combination of mannitol and sucralose, (4) a combination of eriodictyol and sucralose, (5) a combination of menthol and mannitol, or (6) a combination of eriodictyol, mannitol and sucralose.

[0011] In some embodiments, the compounds of the present invention can be used to prevent or treat fatty pancreas, improve pancreatic lesions caused by fatty pancreas, diabetes or other related diseases. In some embodiments, the pancreatic lesions or related disorders include alcoholic fatty pancreatic diseases and non-alcoholic fatty pancreatic diseases, wherein alcoholic fatty pancreatic diseases include but are not limited to alcoholic fatty pancreatitis and alcoholic pancreatitis, and non-alcoholic fatty pancreatic diseases include but are not limited to non-alcoholic fatty steatopancreatitis, pancreatic lipomatosis, pancreatic steatosis, fatty pancreas, lipomatous pseudohypertrophy of pancreas, fatty replacement of pancreas and fatty infiltration of pancreas (Nat. Rev. Gastroenterol. Hepatol. 8, 169-177 (2011); World J Gastroenterol. 2006 Dec. 14;12(46):7421–7427; and Alcohol Clin Exp Res. 1982 Winter;6(1):117-21).

[0012] In some embodiments, the compounds of the present invention can be made into medicines, food additives or health foods.

[0013] In another aspect, the present invention provides a composition comprising a combination of any two or more compounds selected from the group consisting of: poncirin, isovitexin, eriodictyol, ergosterol, β-myrcene, hyperoside, (+)-catechin, palmitic acid ethyl ester, galangin, morin, sciadopitysin, didymin, gossypin, luteolin-7-Glucoside, (+)-taxifolin, trans-cinnamic acid, diosmin, linarin, homoorientin, xylitol, luteolin, swertiamarin, sodium lauryl sulfate, menthol, sucralose, mannitol, crospovidone, sorbitol, saccharin, glycerin, sodium benzoate, oxide red, pregelatinized starch, sodium cyclamate, sorbic acid, lemon oil, maltodextrin, citric acid, and butylated hydroxyanisole, and their derivatives, metabolites and decomposition products.

[0014] In some embodiments, the composition of the present invention includes a combination of any two or more compounds selected from the group consisting of: menthol, mannitol, eriodictyol and sucralose.

[0015] In some embodiments, the composition of the present invention includes a combination selected from the group consisting of: (1) a combination of menthol, mannitol and eriodictyol, (2) a combination of mannitol and eriodictyol, (3) a combination of mannitol and sucralose, (4) a combination of eriodictyol and sucralose, (5) a combination of menthol and mannitol, or (6) a combination of eriodictyol, mannitol and sucralose.

[0016] The present invention also provides that one or more compounds have the effect of regulating pancreatic function, in particular reducing pancreatic function impairment caused by fat accumulation and diabetic symptoms, for example, counteracting insulin resistance and lowering blood sugar.

[0017] The present invention provides one or more compounds described herein, including the compound itself, its derivatives, metabolites, and decomposition products. The aforementioned derivatives include but are not limited to structural isomers, dissociations, salts, esters, chelates or any precursors that can generate the compounds described herein in vivo.

[0018] Without further elaboration, it is believed that those skilled in the art can utilize the present invention to the widest extent based on the above description. Therefore, it is understood that the following description is only for illustrative purposes and does not limit the remaining disclosure in any way. DETAILED DESCRIPTION

[0019] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.

[0020] The terms "a" or "an" as used herein, unless otherwise specified, refer to at least one (one or more than one) quantity.

[0021] The present invention discloses that one or more compounds as described above have the effect of reducing pancreatic fat content, preventing or treating fatty pancreas, improving pancreatic lesions caused by fatty pancreas, diabetes or other related diseases in an individual. Therefore, the present invention provides a use of the compound in the preparation of a composition for reducing pancreatic fat content, preventing or treating fatty pancreas, improving pancreatic lesions caused by fatty pancreas, diabetes or other related diseases in an individual. The present invention also provides a method for reducing pancreatic fat content, preventing or treating fatty pancreas, improving pancreatic lesions caused by fatty pancreas, diabetes or other related diseases, which comprises administering an effective amount of the compound to an individual in need. The present invention also provides a composition for reducing pancreatic fat content, preventing or treating fatty pancreas, improving pancreatic lesions caused by fatty pancreas, diabetes or other related diseases in an individual.

[0022] The one or more compounds disclosed herein include the compound itself, its derivatives, metabolites, and decomposition products. The aforementioned derivatives include but are not limited to structural isomers, dissociations, salts, esters, chelates, or any precursors that can generate the compounds described herein in vivo.

[0023] As used herein, "pancreatic fat content" refers to the fat content accumulated in the pancreas in an individual, including lipids in a broad sense, such as triglycerides (TG) and cholesterol. As used herein, "reducing pancreatic fat content" generally refers to reducing the abnormal pancreatic fat content in an individual to a normal level or closer to a normal level, and may also refer to a comparison of the same individual before and after taking a drug, wherein the pancreatic fat content in the individual after taking the drug is lower than the pancreatic fat content in the individual before taking the drug. The normal level of pancreatic fat content can be obtained by measuring and collecting the pancreatic fat content of normal individuals in a population. For example, for a population, if the normal level of pancreatic fat content is 3% of the weight of the pancreas, when the fat weight in the pancreas exceeds 5% of the weight of the pancreas, it is considered abnormal fat accumulation, then "reducing pancreatic fat content" may refer to reducing the abnormal pancreatic fat content in the individual to 3% of the weight of the pancreas (the above pancreatic fat content is a relative value and is for illustration, and may vary due to individual populations and other factors). As used herein, "fatty pancreas" may refer to a condition in which the pancreatic fat content in an individual is higher than normal. Standard analytical methods can be used to assess pancreatic fat content, including but not limited to ultrasound analysis, magnetic resonance imaging MRI, magnetic resonance spectroscopy MRS, computed tomography CT, and pancreatic pathological sections.

[0024] According to the present invention, the compound includes commonly used excipients and bioflavonoids, which can be easily obtained from this field (such as commercially available), and can be used to reduce pancreatic fat content, prevent or treat fatty pancreas, improve pancreatic lesions caused by fatty pancreas, diabetes or other related diseases in individuals. In some specific embodiments, pancreatic lesions may include diseases caused by abnormal pancreatic fat accumulation, including alcoholic fatty pancreas and non-alcoholic fatty pancreas.

[0025] As used herein, the term "treat" or "treatment" refers to the application or administration of a composition comprising one or more active agents to a subject having a disease, a symptom or condition of a disease, or a worsening of a disease, for the purpose of curing, curing, alleviating, alleviating, altering, remedying, improving, ameliorging, or affecting the disease, a symptom or condition of a disease, a disability caused by the disease, or a worsening of the disease.

[0026] As used herein, the term "prevention" refers to preventative or prophylactic measures against a disease, disease symptom or condition, including, but not limited to, the application or administration of one or more active agents to an individual who may not have been diagnosed with the disease, disease symptom or condition, but is susceptible or predisposed to it, in order to avoid, prevent or delay the onset of the disease, disease symptom or condition.

[0027] As used herein, the terms "individual" or "subject" include humans and non-human animals, such as companion animals (e.g., dogs, cats, etc.), farm animals (e.g., cows, sheep, pigs, horses, etc.), or experimental animals (e.g., rats, mice, guinea pigs, etc.).

[0028] The term "effective amount" as used herein refers to the amount of the active ingredient that produces the desired biological effect or medical effect in the subject being treated, for example, reducing the pancreatic fat content of the subject, preventing or treating fatty pancreas, improving pancreatic lesions caused by fatty pancreas, diabetes or other related diseases.

[0029] In order to achieve the purpose of delivery and absorption, the therapeutically effective amount of the active ingredient according to the present invention can be formulated into a pharmaceutical composition in an appropriate form with a pharmaceutically acceptable carrier.

[0030] The term "pharmaceutically acceptable" as used herein means that the carrier is compatible with the active ingredient of the composition (does not affect the action of the active ingredient), and preferably stabilizes the active ingredient and is safe for the individual receiving the treatment. The carrier may be a diluent, carrier, excipient, or medium for the active ingredient. Some examples of suitable excipients include lactose, glucose, sucrose, sorbitol, mannitol, starch, gum arabic, calcium phosphate, alginate, tragacanth gum, gelatin, calcium silicate, microcrystalline cellulose, polyvinyl pyrrolidone, cellulose, sterile water, syrup, and methylcellulose. The present composition may additionally include lubricants such as talc, magnesium stearate, and mineral oil; wetting agents; emulsifiers and suspending agents; preservatives such as methyl and propyl hydroxybenzoates; sweeteners; and flavoring agents, etc. After administration to the patient, the composition of the present invention can provide a rapid, sustained, or slow release of the active ingredient.

[0031] According to the present invention, the composition can be in any form, for example, tablets, pills, powders, lozenges, capsules, cachets, elixirs, suspensions, emulsions, solutions, syrups, soft and hard gelatin capsules, suppositories, sterile injection solutions, and packaged powders.

[0032] The compositions of the present invention can be delivered via any physiologically acceptable route, for example, oral, parenteral (such as intramuscular, intravenous, subcutaneous, and intraperitoneal), transdermal, suppository, and intranasal methods. For parenteral administration, it is preferred to use a sterile aqueous solution, which may contain other substances, such as salts or glucose sufficient to make the solution isotonic with blood. The aqueous solution may be appropriately buffered (preferably with a pH of 3 to 9) as required. Those skilled in the art can prepare suitable parenteral compositions under sterile conditions by conventional standard pharmacological techniques.

[0033] The present invention also proposes that one or more compounds have the effect of regulating pancreatic function, in particular reducing impaired pancreatic function caused by fat accumulation, for example, diabetic symptoms. The effects of the compounds of the present invention include counteracting insulin resistance and lowering blood sugar. Standard analytical methods can be used to assess impaired pancreatic function and diabetic symptoms, including but not limited to blood glucose level, glycosylated hemoglobin (HbA1C), glucose tolerance test (glucose tolerance test, GTT), blood insulin concentration, homeostasis model assessment of insulin resistance (homeostasis model assessment of insulin resistance, HOMA-IR), tumor necrosis factor-alpha analysis, interleukin-6 (interleukin-6, IL-6) analysis, interleukin-1 beta (interleukin-1 beta, IL-1β) analysis, etc.

[0034] The present invention is further illustrated by the following examples, which are provided for exemplary purposes only and are not intended to limit the present invention. Those skilled in the art will appreciate that, without departing from the spirit and scope of the present invention, many changes may be made to the specific embodiments disclosed herein and the same or similar results may be obtained.

[0035] Examples

[0036] 1. Materials and Methods

[0037] 1.1 Experimental animals

[0038] The experimental animals used were B6 mice. The number of experimental animals in each group was ≥4 in the preliminary test, and ≥12 in the confirmation test. Male mice were raised in an animal room with a normal light-dark cycle (7:00 am to 7:00 pm is the light period, and the rest is the dark period), a temperature of 23±2℃, and a relative humidity of 55±15%, and weighed 18-23g. They were purchased from Lesco Biotechnology Co., Ltd., and animal experiments were conducted in accordance with the experimental guidelines. First, feed 3-5g of general feed per day, raise for 1-2 weeks to observe the health status, and water is supplied unlimitedly. The body weight is recorded once a week.

[0039] 1.2 Animal groups

[0040] The experimental animals were randomly divided into blank control group (Blank), high-fat control group (HFD), positive control group (Positive control, PS) and experimental group. The blank control group was given normal diet; the high-fat control group was given high-fat diet; the positive control group was given high-fat diet and tube-fed silymarin (silymarin, 5mg / kg / day) (Iranian Journal of Pharmaceutical Research (2016), 15(3): 493-500; Life Sciences 75(2004) 2167–2180; and Pharm Biol. 2016 Jul 8: 1-6); and the experimental group was given high-fat diet and tube-fed with individual experimental ingredients.

[0041] 1.3 Feeding method

[0042] The blank control group was fed with normal feed for 12 weeks, while the high-fat control group, positive control group and experimental group were fed with high-fat feed for 12 weeks. After 8 weeks of feeding, the blank control group and high-fat control group were fed with deionized water once a day; the positive control group was fed with silymarin once a day; and the experimental group was fed with the test compound once a day for 4 weeks.

[0043] 1.4 Blood collection and various analyses

[0044] Blood was collected from the cheek or heart before the start of the experiment and at 8 and 12 weeks after the start of the experiment. Finally, all mice were weighed and sacrificed at the end of the experiment, and blood was collected from the cheek or heart. The mouse blood samples were placed at room temperature for 1 hour to allow them to coagulate. Then, they were centrifuged at 15,700xg for 5 minutes at 4°C in a refrigerated centrifuge to separate the serum.

[0045] 1.4.1 Analysis of triglycerides (TG) and total cholesterol (TCHO, TC) in serum

[0046] The triglyceride (TG) and total cholesterol (TCHO, TC) in serum were measured by blood automatic biochemical analyzer.

[0047] 1.4.2 Pancreatic biochemical function analysis: blood glucose analysis (GLU)

[0048] Blood glucose analysis was performed using a Roche ACCU-CHEK Active blood glucose meter. The mice were fasted overnight the day before blood collection. The code card of the blood glucose test strip was inserted into the blood glucose meter, and then the blood glucose test strip was inserted. When a blood drop pattern appeared on the machine, a drop of blood was collected from the cheek vein of the mouse using a cheek needle and dripped into the blood glucose meter test strip, and the blood glucose data displayed by the blood glucose meter was recorded.

[0049] 1.4.3 Pancreatic biochemical function analysis: intraperitoneal glucose tolerance test (IPGTT)

[0050] Move the mice to a clean cage and fast overnight. There is no food or feces in the feeding funnel or bottom of the clean cage. Make sure the animals have access to drinking water at all times. Measure the weight of the mice, and calculate the volume of glucose solution required for intraperitoneally (IP) injection (the concentration is 250 mg / mL, 2 g glucose / mouse body weight, kg, the required volume (μl) is 8x body weight (g)). Move the mice out, inject the appropriate amount of glucose solution into the mice intraperitoneally, and record the injection time. At 0, 15, 30, 60, 120 and 150 minutes after the injection of glucose solution, blood is collected from the tail of the mice to measure the blood glucose concentration, and blood glucose analysis is performed using a Roche ACCU-CHEK Active blood glucose meter. 1.4.4 Pancreatic biochemical function analysis: fasting insulin concentration analysis

[0051] At the end of the experiment (12 weeks), the mice were fasted and blood was collected according to the instructions of the Mouse ultrasensitive insulin ELISA kit (ALPCO).

[0052] 1.4.5 Analysis of pancreatic biochemical function: homeostasis model assessment of insulin resistance (HOMA-IR)

[0053] At the end of the experiment (12 weeks), the mice were fasted and blood was collected to measure blood glucose and insulin concentrations, which were calculated according to the following formula:

[0054]

[0055] 1.4.6 Analysis of triglycerides (TG) and total cholesterol (TCHO, TC) in pancreatic tissue

[0056] After the mice were sacrificed, the pancreas samples were removed by laparotomy and weighed to compare the pancreas weight / body weight ratio. The remaining pancreas was frozen and stored to detect the triglyceride and total cholesterol content in the pancreas.

[0057] 1.5 Statistical analysis

[0058] All data are expressed as mean ± standard deviation (SD). The experimental results were analyzed by one-way analysis of variance (ANOVA) to determine whether they were statistically significant. The Statistical Package of the Social Science program (Version 13, SPSS Inc.) was used for calculation. Post hoc test with the least significant difference method was then used for multiple comparisons to confirm the significant differences between the groups. The significant difference between the group means was set at p < 0.05.

[0059] 2. Results

[0060] 2.1 Animal experiments

[0061] In the animal experiment, except for the blank group which was given normal feed, the other animals were given high-fat feed. After 8 weeks, the animals in each group were given different treatments for 4 weeks in addition to maintaining the original feed. The blank control group and the high-fat control group were given deionized water, the positive control group was given silymarin, and the test group was given different test compounds, including puerarin, phloridzin, eriodictyol, sucralose, mannitol, saccharin, orange peel, menthol, or a combination of some test compounds. There was no statistically significant difference in the weight gain and daily feed intake of the animals among the groups (p>0.05).

[0062] In addition, after the test groups were administered with different test compounds, the animals did not show any abnormal symptoms, no animals died during the test period, and no lesions or clinical symptoms caused by the test compounds were observed when the animals were sacrificed and autopsied after the test. Therefore, the test compounds are safe.

[0063] 2.2 The test compound has the effect of reducing pancreatic lipids

[0064] The results of the animal experiment showed that the various test compounds showed the effect of reducing pancreatic lipid in animals after a 4-week administration period. The results are shown in Table 1.

[0065] Table 1: Test compounds reduce pancreatic lipids in animals (during 4 weeks of dosing).

[0066]

[0067] The results showed that pancreatic triglycerides and total cholesterol increased in mice fed a high-fat diet. When a single test compound was administered, eriodictyol, mannitol, saccharin, sucralose, hesperidin, puerarin, and menthol significantly reduced pancreatic triglycerides by about 33%-87% compared to the high-fat control group. In particular, eriodictyol had an excellent effect after 4 weeks of treatment, reducing pancreatic triglyceride content by about 87% (p<0.005). In addition, eriodictyol, mannitol, saccharin, sucralose, hesperidin, puerarin, menthol, and phlorizin significantly reduced pancreatic total cholesterol by about 28%-51%; in particular, saccharin had an excellent effect after 4 weeks of treatment, reducing pancreatic total cholesterol content by about 51% (p<0.005).

[0068] When two or three compounds are administered in combination, for example, a combination of menthol and mannitol, or a combination of menthol, mannitol and eriodictyol, wherein the dosage of each component is maintained the same as the dosage used alone or the dosage of each component is lower than the dosage used alone (for example, about one-third of the dosage used alone), a similar or better triglyceride lowering effect can be achieved. Therefore, according to the present invention, the combined use of a specific test compound combination can reduce the dosage, but maintain similar or better efficacy, resulting in a synergistic effect.

[0069] 2.3 The test compound has the effect of regulating pancreatic function and treating diabetic symptoms

[0070] The results of animal experiments show that a variety of test compounds can regulate pancreatic function and reduce pancreatic dysfunction in animals during a 4-week administration period, especially for the function of sugar metabolism. The results are shown in Table 2-1.

[0071] Table 2-1: Test compounds can regulate pancreatic function and reduce pancreatic function damage in animals (drug administration period of 4 weeks)

[0072]

[0073]

[0074] Table 2-2: Test compounds can regulate pancreatic function and reduce pancreatic function damage in animals (drug administration period of 4 weeks)

[0075]

[0076]

[0077] This study examines whether the test compound can modulate pancreatic function and reduce the level of pancreatic dysfunction in animals, especially in the glucose metabolism function.

[0078] The results showed that pancreatic carbohydrate metabolism was impaired in mice fed a high-fat diet (GLU, IPGTT, fasting insulin concentration, and HOMA-IR values ​​increased). When a single test compound was administered, sucralose, menthol, mannitol, and saccharin significantly reduced GLU; eriodictyol, sucralose, menthol, mannitol, saccharin, and puerarin significantly reduced glucose tolerance; phloridzin, eriodictyol, sucralose, menthol, mannitol, saccharin, and puerarin significantly reduced fasting insulin concentration and insulin resistance.

[0079] When two or three compounds are administered in combination, for example, a combination of menthol and mannitol, or a combination of menthol, mannitol and eriodictyol, wherein the dosage of each component is lower than the dosage used alone (for example, about one-third of the dosage used alone), similar or better effects of reducing fasting insulin concentration and insulin resistance (significantly reducing fasting insulin concentration, HOMA-IR value) can be achieved. Therefore, according to the present invention, it is shown that the combined use of a specific test compound combination can reduce the dosage of the drug, but maintain similar or better efficacy, with a synergistic effect.

[0080] 2.4 The test compound has the effect of lowering plasma triglycerides

[0081] The results of the animal experiment showed that a variety of test compounds could reduce triglycerides in the plasma of animals during the 4-week administration period. The results are shown in Table 3.

[0082] Table 3: Test compounds can reduce triglycerides in the plasma of animals (drug administration period of 4 weeks)

[0083]

[0084]

[0085] The results showed that high-fat diet induced an increase in plasma triglycerides in mice. When administered with a single test compound, eriodictyol and phlorizin significantly reduced plasma triglycerides, with the highest reduction being about 27% compared to the high-fat control group.

[0086] When the two test compounds were administered in combination, the combination of menthol and mannitol or the combination of eriodictyol and sucralose significantly reduced plasma triglycerides.

[0087] When the three test compounds were administered in combination, the combination of menthol, mannitol and eriodictyol was effective in lowering plasma triglycerides at low doses.

[0088] The compounds provided by the present invention can reduce pancreatic fat content and improve related symptoms in individuals. These compounds are low-molecular natural plant phenolic compounds, which are widely found in fruits and vegetables, grains, rhizomes, flowers, tea and red wine. They have been confirmed to be safe through animal experiments and have the potential to be developed into health foods or drugs for reducing pancreatic fat, preventing or treating fatty pancreas, improving pancreatic lesions caused by fatty pancreas, diabetes or other related symptoms, regulating pancreatic function, and especially improving insulin resistance.

Claims

1. A use of a compound for preparing a composition for reducing pancreatic fat content, preventing or treating fatty pancreas, or improving pancreatic lesions or other related diseases caused by fatty pancreas in an individual, wherein the compound is selected from the group consisting of: citrus glycoside, isovitexin, eriodictyol, ergosterol, myrcene, hyperoside, catechin, ethyl hexadecanoate, galangin, morin, golden pine biflavonoids, fennel glycosides, cotton cellulose, luteolin-7-glucoside, dihydroquercetin, cinnamic acid, diosmetin, monanthin, isoerythrin, xylitol, luteolin, swertiarin, sodium laurate sulfate, menthol, sucralose, mannitol, cross-linked polyvidone, sorbitol, saccharin, glycerin, sodium benzoate, red iron oxide, pregelatinized starch, sodium cyclohexanesulfamate, sorbic acid, lemon oil, maltodextrin, citric acid, and butylated hydroxyanisole, and any combination thereof.

2. The use according to claim 1, wherein the compound is selected from the group consisting of menthol, mannitol, eriodictyol, sucralose and any combination thereof.

3. The use according to claim 1, wherein the compound is 1) a combination of menthol, mannitol and eriodictyol, 2) a combination of mannitol and eriodictyol, 3) a combination of mannitol and sucralose, 4) a combination of eriodictyol and sucralose, 5) a combination of menthol and mannitol, or 6) a combination of eriodictyol, mannitol and sucralose.

4. The use according to claim 1, wherein the related disease is alcoholic fatty pancreas and non-alcoholic fatty pancreas.

5. The use according to claim 1, wherein the composition is a medicine, a food additive or a health food.

6. A composition for reducing pancreatic fat content, preventing or treating fatty pancreas, improving pancreatic lesions caused by fatty pancreas or other related diseases in an individual, comprising a combination of any two or more compounds selected from the group consisting of: sodium lauryl sulfate, menthol, sucralose, mannitol, crospovidone, sorbitol, saccharin, glycerin, sodium benzoate, red iron oxide, pregelatinized starch, sodium cyclohexanesulfamate, sorbic acid, lemon oil, maltodextrin, citric acid, butylated hydroxyanisole, citric acid, isovitexin, eriodictyol, ergosterol, myrcene, hyperoside, catechin, hexadecanoic acid ethyl ester, galangin, morin, golden pine biflavonoids, fennel glycosides, cotton cellulose, luteolin-7-glucoside, dihydroquercetin, cinnamic acid, diosmetin, monanthin, isoerythrin, xylitol, luteolin and swertiamarin.

7. The composition according to claim 6, comprising a combination of any two or more compounds selected from the group consisting of menthol, mannitol, eriodictyol and sucralose.

8. The composition of claim 6, comprising a combination selected from the group consisting of: 1) a combination of menthol, mannitol and eriodictyol, 2) a combination of mannitol and eriodictyol, 3) a combination of mannitol and sucralose, 4) a combination of eriodictyol and sucralose, 5) a combination of menthol and mannitol, or 6) a combination of eriodictyol, mannitol and sucralose.

9. The composition according to claim 6, which is used in an individual to reduce pancreatic fat content, prevent or treat fatty pancreas, improve pancreatic lesions caused by fatty pancreas, diabetes or other related diseases.

10. The composition according to claim 9, wherein the related disorders are alcoholic fatty pancreas and non-alcoholic fatty pancreas. The composition according to claim 6, which is a medicine, a food additive or a health food.

Images